Media Articles Related to Levatol (Penbutolol)
Deaths from pulmonary hypertension have increased, say CDC
Source: Hypertension News From Medical News Today [2014.04.04]
A study from the CDC finds that deaths from pulmonary hypertension - high blood pressure in the arteries leading from the heart to the lungs - have increased over the past decade.
Pseudotumor Cerebri (Idiopathic Intracranial Hypertension)
Source: MedicineNet Brain Aneurysm Specialty [2014.04.02]
Title: Pseudotumor Cerebri (Idiopathic Intracranial Hypertension)
Category: Diseases and Conditions
Created: 11/8/1998 8:47:00 PM
Last Editorial Review: 4/2/2014 12:00:00 AM
Children with glomerular kidney disease more likely to have hypertension as adults
Source: Hypertension News From Medical News Today [2014.03.20]
Men who as children had glomerular disease, a disorder of the portion of the kidney that filters blood and one that usually resolves with time, were more likely than men without childhood...
Guidelines on the management of pulmonary hypertension of sickle cell disease
Source: Hypertension News From Medical News Today [2014.03.18]
The American Thoracic Society has developed clinical practice guidelines to help clinicians identify and manage patients with sickle cell disease who are at increased risk for mortality from...
Source: MedicineNet Congestive Heart Failure Specialty [2013.11.25]
Title: Pulmonary Hypertension
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 11/25/2013 12:00:00 AM
Published Studies Related to Levatol (Penbutolol)
[The noninvasive assessment of the effects of penbutolol on liver hemodynamics in cirrhotic patients using angioscintigraphy. A randomized controlled double-blind study] [1990.11]
This randomized double-blind controlled study analyzed the hemodynamic effects of penbutolol, a new levo-rotatory betablocker, using radionuclide angiography. Twenty cirrhotics with esophageal varices were randomized: 10 received 40 mg/day of penbutolol orally and the others a placebo...
The influence of penbutolol and placebo on blood sugar levels and insulin consumption in the glucose-controlled insulin infusion system ("artificial endocrine pancreas"). [1990.10.03]
The aim of the study was to investigate the influence of 40 mg of the beta-blocker penbutolol (Betapressin TM; Hoechst Ltd., Frankfurt/Main) in comparison to placebo on the insulin consumption on the blood sugar profile in twelve insulin-dependent diabetes (IDDM) patients...
Angioscintigraphic assessment of hemodynamic effects of penbutolol in cirrhotics with portal hypertension. A double-blind, randomized, controlled study. [1990.08]
This randomized double-blind controlled study analyzed the hemodynamic effects of penbutolol, a new levorotatory beta-blocker, using radionuclide angiography. Twenty cirrhotics with esophageal varices were randomized to two groups: 10 received 40 mg/day of penbutolol orally and the others placebo...
Penbutolol in the treatment of mild to moderate essential hypertension in black South Africans. [1990.06]
The antihypertensive effects of penbutolol, a nonselective beta-adrenoceptor antagonist with intrinsic sympathomimetic activity, was assessed in nonobese black South Africans aged 25 to 65 years with uncomplicated mild to moderate essential hypertension...
Effects of penbutolol on plasma atrial natriuretic peptide and antidiuretic hormone levels before and after exercise: a double-blind comparison against placebo. 
A double-blind crossover trial was carried out in 7 healthy male volunteers to investigate the effects of penbutolol and a placebo on plasma atrial natriuretic peptide (ANP) and antidiuretic hormone (ADH) levels before and after exercise. Each subject underwent several bicycle ergometric exercises lasting 6 min before and after the application of test medications...
Clinical Trials Related to Levatol (Penbutolol)
Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension [Completed]
Plasma renin values determine whether volume or vasoconstrictor (renin) factors predominate
in elevating blood pressure and are useful in selecting effective antihypertensive
The researchers hypothesize that:
1. Plasma renin-guided therapeutics will improve systolic and diastolic blood pressure
control in patients with untreated hypertension as well as in patients with treatment
refractory or resistant hypertension that are managed by Clinical Hypertension
2. Renin-guided therapeutics will reduce the number of medications required to maintain
blood pressure control to <140/90 mmHg in hypertensive patients receiving 3 or more
medications, while under the care of a Clinical Hypertension Specialist.
3. Renin-guided therapeutics selection will reduce the total cost of antihypertensive care
provided by Clinical Hypertension Specialists.